{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010176","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.562114+00:00","generated_at":"2026-05-17T20:46:32.459567+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rhythm Pharma Q2 revenue $48.5M (+29% seq), net loss $(48.0M); advances setmelanotide filings for AHO","bullets":["Q2 net product revenue $48.5M, up 29% sequentially from Q1 2025; US revenue $32.0M (66% of total), up 31%.","Net loss $(48.0)M ($(0.75)/share) vs $(33.6)M ($(0.55)/share) in Q2 2024.","Cash $291M at June 30; added ~$189.2M from July stock offering; paid $40M to LG Chem for bivamelagon.","Phase 3 TRANSCEND: setmelanotide achieved placebo-adjusted BMI reduction of -19.8% in acquired hypothalamic obesity (AHO).","Regulatory submissions for setmelanotide in AHO to FDA and EMA on track for Q3 2025; FY 2025 Non-GAAP OpEx guidance $285-315M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010176","json":"https://secwatch.observer/filing/0001558370-25-010176.json","markdown":"https://secwatch.observer/filing/0001558370-25-010176.md","text":"https://secwatch.observer/filing/0001558370-25-010176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000155837025010176/0001558370-25-010176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000155837025010176/rytm-20250805x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:46:32.459567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}